FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.

Saved in:
Bibliographic Details
Title: FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Authors: Simpson AP; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Roghanian A; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK; Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK., Oldham RJ; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Chan HTC; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Penfold CA; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Kim HJ; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Inzhelevskaya T; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Mockridge CI; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Cox KL; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Bogdanov YD; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., James S; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Tutt AL; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Rycroft D; Biopharm Discovery, GSK, Gunnels Wood Road, Stevenage SG1 2NY, UK., Morley P; Biopharm Discovery, GSK, Gunnels Wood Road, Stevenage SG1 2NY, UK., Dahal LN; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK., Teige I; BioInvent International AB, Sölvegatan 41, 22370 Lund, Sweden., Frendeus B; BioInvent International AB, Sölvegatan 41, 22370 Lund, Sweden. Electronic address: bjorn.frendeus@bioinvent.com., Beers SA; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK. Electronic address: sab@soton.ac.uk., Cragg MS; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK; Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK. Electronic address: msc@soton.ac.uk.
Source: Cell reports [Cell Rep] 2022 Jul 19; Vol. 40 (3), pp. 111099.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2211-1247
DOI:10.1016/j.celrep.2022.111099